Boyang Yu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9840923/publications.pdf

Version: 2024-02-01

		1684188	1872680	
7	260	5	6	
papers	citations	h-index	g-index	
7 all docs	7 docs citations	7 times ranked	367 citing authors	

#	Article	IF	CITATIONS
1	YiQiFuMai lyophilized injection attenuates cerebral ischemic injury with inhibition of neuronal autophagy through intervention in the NMMHC IIA–actin—ATG9A interaction. Phytomedicine, 2022, 95, 153882.	5.3	O
2	The myosin II inhibitor, blebbistatin, ameliorates pulmonary endothelial barrier dysfunction in acute lung injury induced by LPS via NMMHC IIA/Wnt5a/ \hat{l}^2 -catenin pathway. Toxicology and Applied Pharmacology, 2022, 450, 116132.	2.8	5
3	Endothelial Conditional Knockdown of NMMHC IIA (Nonmuscle Myosin Heavy Chain IIA) Attenuates Blood-Brain Barrier Damage During Ischemia-Reperfusion Injury. Stroke, 2021, 52, 1053-1064.	2.0	19
4	NMMHC IIA triggers neuronal autophagic cell death by promoting F-actin-dependent ATG9A trafficking in cerebral ischemia/reperfusion. Cell Death and Disease, 2020, 11, 428.	6.3	17
5	Myosin IIA-related Actomyosin Contractility Mediates Oxidative Stress-induced Neuronal Apoptosis. Frontiers in Molecular Neuroscience, 2017, 10, 75.	2.9	39
6	Ruscogenin Attenuates Cerebral Ischemia-Induced Blood-Brain Barrier Dysfunction by Suppressing TXNIP/NLRP3 Inflammasome Activation and the MAPK Pathway. International Journal of Molecular Sciences, 2016, 17, 1418.	4.1	144
7	NMMHC IIA inhibition impedes tissue factor expression and venous thrombosis via Akt/GSK3β-NF-κB signalling pathways in the endothelium. Thrombosis and Haemostasis, 2015, 114, 173-185.	3.4	36